Paracetamol-induced fixed drug eruption at an unusual site

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 3, 2013, Pages 268-270

  Gómez Traseira, Carmen ^a   Rojas Pérez Ezquerra, Patricia ^a   Sánchez Morillas, Leticia ^a   González Mendiola, Rosario ^a   Rubio Pérez, María ^a   Moral Morales, Alicia ^a   Laguna Martinez, José Julio ^a  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

Author keywords

Allergy; Fixed drug eruption; Paracetamol

Indexed keywords

BIPHENYLOXYACETIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; GLYCOLIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DELAYED HYPERSENSITIVITY; DRUG TOLERANCE; ERYTHEMA; FEMALE; FIXED DRUG ERUPTION; HARD PALATE; HUMAN; INTRACUTANEOUS TEST; MACULOPAPULAR RASH; PATCH TEST; PATENT; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; DRUG ERUPTIONS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; MIDDLE AGED; PALATE; PATENTS AS TOPIC; SKIN TESTS;

EID: 84888250033     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872213X113079990018     Document Type: Article

References (15)

1. Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions-a 20-year review. Contact Dermatitis 2011: 65: 195-201.
2. Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol 2010; 20: 46-4.
3. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Drug related clinical pattern in fixed drug eruption. Eur J Dermatol 2000; 10(4):288-91.
4. Gómez Martínez M, Fernández de Miguel C, Domínguez Lázaro A, Laguna Martínez JJ, Orta Martiartu M, Lozano Ayllón M. Fixed exanthema due to paracetamol. J Investing Allergol Clin Immunol 1996: 6: 131-2.
5. Silva A, Proença E, Carvalho C, Senra V, Rosário C. Fixed drug eruption induced by paracetamol. Pediatr Dermatol 2001: 18: 163-4.
6. Galindo PA, Borja J, Feo F, Gómez E, Encinas C, García R. Nonpigmented fixed drug eruption caused by paracetamol. J Investig Allergol Clin Immunol 1999: 9: 399-400.
7. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45(6): 321-8.
8. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002: 57: 45-51.
9. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. European Network for Drug Allergy (ENDA); EAACI interest group on drughypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003: 58: 854-63.
10. Shiohara T, Mizukawa Y. Fixed drug eruption: A disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17(3): 201-8.
11. Astrazeneca, A.B. Novel piperidinederivatives. US20130023562 (2013).
12. Astrazeneca, A.B. Biphenyloxyacetic acid derivatives for the treatment of respiratory disease. US8415394 (2013).
13. Austin, T., O'Sullivan, D., Perry, M., Springthorpe, B. Piperidine derivatives. US8314127 (2012).
14. Bonnert, R.V., Thom, S., Patel, A., Luker, T.J. Substituted acids for the treatment of respiratory diseases. US8022248 (2011).
15. Chen, Y.-T., Hung, S.-I., Chung, W.-H., Wu, J.-Y. Risk assessment for adverse drug reactions. US7964351 (2011).